ClinicalTrials.gg

Program

Ranibizumab

Also written as “ranibizumab”, “Ranibizumab 0.5 mg” and “rhuFab V2 (ranibizumab)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Choroidal Neovascularization · Retinal Vein Occlusion · Vision Disorders, led by 16 companies.

Furthest: phase 4, since Jul 19, 200798 company-led studies, 6 open or runningNext primary completion: Feb 4, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis560 open or runningphase 4since Jul 19, 2007Jan 11, 2006none ahead
Hoffmann-La Roche244 open or runningphase 4since Jan 13, 2011Mar 24, 2003Feb 4, 2027phase 3 · NCT04657289
AbbVie31 open or runningphase 4since Aug 31, 2011Oct 16, 2008Jul 2031phase 2 · NCT05210803
Samsung Bioepis20 open or runningphase 2since Dec 11, 2023Dec 11, 2023none ahead
Santen Pharmaceutical20 open or runningphase 2since Oct 1, 2008Oct 1, 2008none ahead
AO GENERIUM11 open or runningphase 3since Nov 30, 2020Nov 30, 2020none ahead
bioeq-gmbh10 open or runningphase 3since Nov 19, 2015Nov 19, 2015none ahead
Cynosure Lutronic10 open or runningphase 4since Nov 27, 2018Nov 27, 2018none ahead
Formycon10 open or runningphase 4since Nov 25, 2024Nov 25, 2024none ahead
Incepta Pharmaceuticals10 open or runningphase 3since Mar 5, 2024Mar 5, 2024none ahead
oraya-therapeutics-inc10 open or runningno phasesince Jan 24, 2012Jan 24, 2012none ahead
pfenex-inc10 open or runningphase 2since Apr 17, 2014Apr 17, 2014none ahead
Qilu Pharmaceutical10 open or runningphase 1since Oct 12, 2017Oct 12, 2017none ahead
qlt-inc10 open or runningphase 2since Jun 25, 2007Jun 25, 2007none ahead
shanghai-biomabs-pharmaceutical-co-ltd10 open or runningphase 1since May 6, 2021May 6, 2021none ahead
xbrane-biopharma-ab10 open or runningphase 3since Jan 8, 2019Jan 8, 2019none ahead

Also a collaborator on its studies: regenxbio-inc, stada-arzneimittel-ag and macusight-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Mar 11, 2011.

  1. Aug 5, 2020Phase 3 study in Diabetic RetinopathyHoffmann-La Roche · NCT04503551 · 174 enrolled · United States, Puerto Rico
  2. Sep 24, 2020Phase 2 study in Macular DegenerationHoffmann-La Roche · NCT04567303 · 177 enrolled · United States, Puerto Rico
  3. Nov 30, 2020AO GENERIUM's first study: phase 3 study in Macular DegenerationNew to AO GENERIUMAO GENERIUM · NCT04667039 · 408 planned · Russian Federation
  4. Dec 1, 2020Phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)Hoffmann-La Roche · NCT04657289 · 451 enrolled · Argentina, Australia, Austria and more
  5. Apr 16, 2021Phase 4 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT04853251 · 188 enrolled · United States
  6. May 6, 2021shanghai-biomabs-pharmaceutical-co-ltd's first study: phase 1 study in Wet Age-related Macular DegenerationNew to shanghai-biomabs-pharmaceutical-co-ltdshanghai-biomabs-pharmaceutical-co-ltd · NCT04884399 · 24 enrolled · China
  7. Oct 28, 2021Phase 3 study in Neovascular Age-Related Macular DegenerationHoffmann-La Roche · NCT05126966 · Argentina, Denmark, Greece and more
  8. Jan 14, 2022Phase 2 study in Neovascular Age-Related Macular Degeneration (nAMD)AbbVie · NCT05210803 · 116 planned · United States
  9. Sep 15, 2022Phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT05562947 · 68 enrolled · China
  10. Dec 11, 2023Samsung Bioepis's first study: phase 2 study in Macular EdemaNew to Samsung BioepisSamsung Bioepis · NCT06176963 · 34 enrolled · Poland
  11. Mar 5, 2024Incepta Pharmaceuticals's first study: phase 3 study in Diabetic RetinopathyNew to Incepta PharmaceuticalsIncepta Pharmaceuticals · NCT06305416 · 70 enrolled · Bangladesh
  12. Nov 25, 2024Formycon's first study: phase 4 study in Macular DegenerationNew to FormyconFormycon · NCT06708624 · 31 enrolled · United States
  13. Feb 21, 2025Phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT06847542 · 250 planned · Austria, Czechia, Denmark and more
  14. Apr 19, 2026Phase 2 study in Macular DegenerationSamsung Bioepis · NCT07550504 · 30 enrolled · Poland

Ahead

  1. Feb 4, 2027Primary completion: phase 3 study in Neovascular Age-related Macular Degeneration (nAMD)Hoffmann-La Roche · NCT04657289
  2. Jun 30, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT05562947
  3. Jul 30, 2027Primary completion: phase 4 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT04853251
  4. Nov 15, 2028Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationHoffmann-La Roche · NCT06847542

TargetBeta

VEGFA →read by rule
“A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
suvemcitugruleSimcere Pharmaceutical Groupphase 36
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

The newest 60 of 98 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07550504Macular Degeneration · Poland2CompletedSamsung BioepisMar 31, 202630
NCT06847542Neovascular Age-related Macular Degeneration · Austria, Czechia, Denmark and more3RecruitingHoffmann-La RocheNov 15, 2028250
NCT06708624Macular Degeneration · United States4CompletedFormyconAug 8, 202431
NCT06305416Diabetic Retinopathy · Bangladesh3CompletedIncepta PharmaceuticalsMar 10, 202670
NCT06176963Macular Edema · Poland2CompletedSamsung BioepisNov 30, 202334
NCT05562947Neovascular Age-related Macular Degeneration · China3Active, not recruitingHoffmann-La RocheJun 30, 202768
NCT05210803Neovascular Age-Related Macular Degeneration (nAMD) · United States2By invitationAbbVieJul 2031116
NCT05126966Neovascular Age-Related Macular Degeneration · Argentina, Denmark, Greece and more3WithdrawnHoffmann-La RocheJan 31, 20250
NCT04884399Wet Age-related Macular Degeneration · China1Completedshanghai-biomabs-pharmaceutical-co-ltdDec 22, 202224
NCT04853251Neovascular Age-related Macular Degeneration · United States4Active, not recruitingHoffmann-La RocheJul 30, 2027188
NCT04657289Neovascular Age-related Macular Degeneration (nAMD) · Argentina, Australia, Austria and more3Active, not recruitingHoffmann-La RocheFeb 4, 2027451
NCT04667039Macular Degeneration · Russian Federation3RecruitingAO GENERIUMAug 15, 2024408
NCT04567303Macular Degeneration · United States, Puerto Rico2CompletedHoffmann-La RocheAug 25, 2026177
NCT04503551Diabetic Retinopathy · United States, Puerto Rico3CompletedHoffmann-La RocheOct 3, 2022174
NCT03927690Macular Degeneration · United States, Germany, Puerto Rico and more2CompletedNovartisJun 17, 202291
NCT03805100Macular Degeneration · United States, Bulgaria, Czechia and more3Completedxbrane-biopharma-abMay 11, 2021582
NCT03759860Diabetic Macular Edema · Korea, Republic of4UNKNOWNCynosure LutronicJul 30, 201912
NCT03312283Wet Age-related Macular Degeneration · China1CompletedQilu PharmaceuticalApr 2, 201948
NCT03211234Macular Degeneration · United States, Philippines2CompletedSanten PharmaceuticalDec 31, 201976
NCT02878681Visual Impairment Due to Diabetic Macular Edema4WithdrawnNovartisSep 20170
NCT02698566Macular Edema · United States3CompletedHoffmann-La RocheApr 5, 201635
NCT02634970Neovascularization, Pathologic4WithdrawnNovartisDec 20170
NCT02640664Retinopathy of Prematurity · United States, Austria, Belgium and more3CompletedNovartisApr 21, 2022180
NCT02611778Macular Degeneration · Austria, Czechia, France and more3Completedbioeq-gmbhDec 2017712
NCT02577107Macular Degeneration · China4CompletedNovartisJul 9, 201612
NCT02510794Macular Degeneration · United States2CompletedHoffmann-La RocheApr 10, 2018225
NCT02484690Choroidal Neovascularization · United States2CompletedHoffmann-La RocheSep 26, 2017273
NCT02375971Retinopathy of Prematurity · United States, Austria, Belgium and more3CompletedNovartisDec 14, 2017224
NCT02366468Diabetic Retinopathy · Germany4CompletedNovartisJun 8, 2017135
NCT02259088Vision Disorders · China3CompletedNovartisJan 17, 2017384
NCT02258009Visual Impairment Due to Diabetic Macular Edema · Germany4WithdrawnNovartisOct 20160
NCT02257632Wet Age-Related Macular Degeneration · Germany4CompletedNovartisMar 20, 201741
NCT02161575Macular Degeneration · Germany, United Kingdom4CompletedNovartisSep 14, 2017103
NCT02121353Macular Degeneration · New Zealand2Completedpfenex-incJan 201625
NCT02130024Macular Degeneration · Australia4CompletedNovartisNov 15, 2017281
NCT02034006Myopia, Degenerative · Italy3CompletedNovartisJul 15, 2016200
NCT02032173Macular Edema · France3TerminatedNovartisApr 29, 201531
NCT01986907Macular Degeneration · Italy4CompletedNovartisJun 15, 20161,049
NCT01972789Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD · Australia4CompletedNovartisFeb 28, 2017349
NCT01976338Macular Edema · China, Hong Kong, Indonesia and more3CompletedNovartisMar 28, 2016283
NCT01976312Retinal Vein Occlusion · China, Hong Kong, India and more3CompletedNovartisMar 14, 2016252
NCT01958918Neovascular Age-related Macular Degeneration · Austria, Belgium, Denmark and more4CompletedNovartisNov 22, 2016712
NCT01948830Macular Degeneration · Belgium, Chile, Croatia and more3CompletedNovartisNov 19, 2015650
NCT01922102Choroidal Neovascularization · China, Hong Kong, India and more3CompletedNovartisSep 14, 2016457
NCT01908816Choroidal Neovascularization · France3CompletedNovartisJan 8, 2016270
NCT01846299Macular Edema · Australia, Belgium, Canada and more3CompletedNovartisSep 2015181
NCT01840410Choroidal Neovascularization · Australia, Canada, Czech Republic and more3CompletedNovartisNov 2015183
NCT01780935Neovascular Age-related Macular Degeneration · Argentina, Austria, Canada and more3CompletedNovartisJul 9, 2015671
NCT01775124Macular Degeneration · China4CompletedNovartisNov 23, 2015332
NCT01594281Proliferative Diabetic Retinopathy (PDR) · Germany2CompletedNovartisNov 30, 2016107
NCT01599650Retinal Vein Occlusion · Australia, Canada, Czech Republic and more3CompletedNovartisMay 2015455
NCT01580020Retinal Vein Occlusion · Germany4CompletedNovartisOct 2014175
NCT01535261Macular Edema · Australia, Austria, Canada and more3CompletedNovartisMar 2015357
NCT01521819Macular Degeneration · Italy–UNKNOWNoraya-therapeutics-incAug 201312
NCT01442064Macular Edema–CompletedHoffmann-La RocheJul 2010608
NCT01427751Retinal Vein Occlusion · France, Germany, Israel and more4CompletedAbbVieNov 4, 2014307
NCT01396083Vision Disorders · Germany, Hungary, Poland and more3CompletedNovartisJan 2014243
NCT01396057Vision Disorders · Czech Republic, Germany, Hungary and more3CompletedNovartisJun 2013244
NCT01377597Retinal Vein Occlusion · Japan3CompletedNovartisApr 201247
NCT01315275Vision Disorders · France4CompletedNovartisAug 2012394

How it is read

Names in the registry

  • “Ranibizumab”, 40 entries
  • “ranibizumab”, 18 entries
  • “Ranibizumab 0.5 mg”, 11 entries
  • “rhuFab V2 (ranibizumab)”, 6 entries
  • “Ranibizumab 0.5mg”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.